  0086-18989305995        sales@mosinterchem.com
You are here: Home / Products-list / Pharmaceutical Chemicals API / Antineoplastic Drugs API / Epirubicin CAS 56420-45-2 Pharmarubicin

PRODUCT CATEGORY

PRODUCTS DETAILS

loading

Epirubicin CAS 56420-45-2 Pharmarubicin

Place of Origin:Zhejiang,China (Mainland)
Brand:MOSINTER
Molecular Formula:C27H29NO11
Specification:CP/USP/EP
  • 56420-45-2

  • MOSINTER

  • 56420-45-2

Availability:
Product Description

Payment & Shipping Terms

Supply Capacity

Payment Terms:

T/T, WU

Production Capacity:

1000kg/year

Min. Order:

1 Gram

Packing:

according to the customer's requirements 

Means of Transport:

Ocean, Air, Land

Delivery Date:

7 days

 

Epirubicin

CAS 56420-45-2

Epirubicin is one of the drugs selected to treat solid tumors. It acts directly on DNA, interferes with and prevents DNA replication and transcription. It affects the function of mitochondria by inhibiting the activities of respiratory enzymes such as succinate oxidase and NADPH oxidase. It has been found that it can induce apoptosis of cancer cells, which may occur through the mitochondrial pathway of apoptosis. Due to its excretion through the hepatobiliary system, the patients with liver dysfunction should be reduced to avoid accumulation of poisoning; for patients with moderate liver dysfunction (bilirubin 1.4-3mg / 100ml or BSP retention 9-15%), the dosage should be reduced by 50%; for patients with severe liver dysfunction (bilirubin > 3mg / 100ml or BSP retention > 15%), the dosage should be reduced by 75%; for patients with moderate renal dysfunction, there is no need to reduce the dosage, because Only a small amount of the drug is excreted through the kidney. The usage is intravenous administration. It is suggested to inject normal saline first to check the patency of the infusion tube and after the injection needle is indeed in the vein, then to give medicine through the patency of the infusion tube. This method can reduce the risk of drug spillover and ensure that the vein is flushed with saline after administration. If epirubicin overflows the vein during injection, it will cause serious tissue damage or even necrosis. If the same vein is injected in small vein or repeatedly, it will cause venous sclerosis. It cannot be mixed with heparin, because the chemical properties of the two are not compatible, and precipitation reaction will occur at a certain concentration. It can be used with other anti-tumor drugs, but the dosage of epirubicin should be reduced, not in the same syringe Mixed drugs.

We can customize according to customer's requirement

if you have any question pls mail us or call us.


Previous: 
Next: 
PRODUCT INQUIRY
If you would like to have a question then get in touch today, we are ready to assist 24/7.
We welcome your cooperation and we will develop with you.
Factory-direct Connectivity Solutions.
High quality, Competitive Price.
Custom-tailored solutions.
Problem-solving approach.

ABOUT US

MOSINTER GROUP was established in 2004. The main office is located in Ningbo, China. The production are located in Zhejiang Province, Jiangsu Province and Shandong Province in China. Specializing in the production and marketing of chemical products, MOSINTER GROUP has excellent production equipment and a high-performing sales team as well as advanced manufacturing technique, comprehensive quality management system and modernized testing methods.

QUICK LINK

CONTACT INFO

  0086-18989305995
 0086-574-88212215
  sales@mosinterchem.com
  YinXianDaDao 1357, Guangbo Center Office 2003, Ningbo, Zhejiang, China
 forwardcy
 0086-18989305995
 0086-18989305995
Copyright  2020 Mosinter Group Limited All rights reserved.